CME/CE

Use the tool below to view all available Global Kidney Academy Series

The Hidden Danger of IgAN: Pathogenesis and Unmet Needs
The Hidden Danger of IgAN: Pathogenesis and Unmet Needs
MinuteCE®
The Hidden Danger of IgAN: Pathogenesis and Unmet Needs
Jonathan Barratt, MD, PhD
1.00 program credit
- Jonathan Barratt, MD, PhD
1.00 program credit
Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal
Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal
MinuteCE®
Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal
Jonathan Barratt, MD, PhD; An De Vriese, MD, PhD
1.00 program credit
- Jonathan Barratt, MD, PhD
- An De Vriese, MD, PhD
1.00 program credit
Translating Evidence into IgAN Care
Translating Evidence into IgAN Care
MinuteCE®
Translating Evidence into IgAN Care
Jonathan Barratt, MD, PhD; Jörg Latus, MD
1.00 program credit
- Jonathan Barratt, MD, PhD
- Jörg Latus, MD
1.00 program credit
The Future of IgAN Care
The Future of IgAN Care
MinuteCE®
The Future of IgAN Care
Chee Kay Cheung, MBChB, MRCP, PhD; An De Vriese, MD, PhD
1.00 program credit
- Chee Kay Cheung, MBChB, MRCP, PhD
- An De Vriese, MD, PhD
- Jörg Latus, MD
1.00 program credit
The Evolving Role of Biomarkers in IgAN
The Evolving Role of Biomarkers in IgAN
MinuteCE®
The Evolving Role of Biomarkers in IgAN
Chee Kay Cheung, MBChB, MRCP, PhD
1.00 program credit
- Chee Kay Cheung, MBChB, MRCP, PhD
1.00 program credit
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
CME/CE
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
Gianluigi Savarese, MD, PhD, FESC, FHFA
0.25 credits
- Gianluigi Savarese, MD, PhD, FESC, FHFA
0.25 credits
Gabapentinoids: Safety Considerations and Downstream Outcomes
Gabapentinoids: Safety Considerations and Downstream Outcomes
MinuteCE®
Gabapentinoids: Safety Considerations and Downstream Outcomes
Federico Alberici, MD, PhD; Anastasia Liossatou, PhD, RN
1.00 program credit
- Federico Alberici, MD, PhD
- Anastasia Liossatou, PhD, RN
1.00 program credit
Frontline Champions: Nurses as Drivers of Symptom-Based CKD-aP Care
Frontline Champions: Nurses as Drivers of Symptom-Based CKD-aP Care
MinuteCE®
Frontline Champions: Nurses as Drivers of Symptom-Based CKD-aP Care
Federico Alberici, MD, PhD; Anastasia Liossatou, PhD, RN
1.00 program credit
- Federico Alberici, MD, PhD
- Anastasia Liossatou, PhD, RN
1.00 program credit
From Scratch to Strategy: Talking About CKD-aP in Clinical Practice
From Scratch to Strategy: Talking About CKD-aP in Clinical Practice
MinuteCE®
From Scratch to Strategy: Talking About CKD-aP in Clinical Practice
Federico Alberici, MD, PhD; Anastasia Liossatou, PhD, RN
1.00 program credit
- Federico Alberici, MD, PhD
- Anastasia Liossatou, PhD, RN
1.00 program credit
What You Don’t See: A Patient’s View of Living with CKD-aP
What You Don’t See: A Patient’s View of Living with CKD-aP
MinuteCE®
What You Don’t See: A Patient’s View of Living with CKD-aP
Steven Fishbane, MD; Nancy Helou, PhD
1.00 program credit
- Steven Fishbane, MD
- Nancy Helou, PhD
1.00 program credit
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
CME/CE
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD; Julio Núñez, MD, PhD
0.25 credits
- Patrick Rossignol, MD, PhD
- Julio Núñez, MD, PhD
0.25 credits
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
CME/CE
Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN
Chee Kay Cheung, MBChB, MRCP, PhD; Claudia Seikrit, MD
0.25 credits
- Chee Kay Cheung, MBChB, MRCP, PhD
- Claudia Seikrit, MD
0.25 credits
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
CME/CE
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Antoine Lanot, MD, PhD; Gil Yosipovitch, MD
0.25 credits
- Antoine Lanot, MD, PhD
- Gil Yosipovitch, MD
0.25 credits
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Inside the IgAN Clinic: Shared Decision-Making Into Practice
CME/CE
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Jonathan Barratt, MD, PhD
0.25 credits
- Jonathan Barratt, MD, PhD
0.25 credits
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
CME/CE
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Steven Fishbane, MD; Maurizio Gallieni, MD
0.25 credits
- Steven Fishbane, MD
- Maurizio Gallieni, MD
0.25 credits
MinuteCE®
Decoding Itch in CKD: From CKD-aP Suspicion to Solution
James Burton, DM, FRCP; Leonie Kraft, MD
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Leonie Kraft, MD
- Lucio Manenti, MD, PhD
- Emilio Sanchez, MD, PhD
1.00 credit 9 episodes

CME/CE

Popular

Title

Welcome to Global Kidney Academy

Welcome to Global
Kidney Academy